Trump Locks In 17 Drug Pricing Deals — $529 Billion in Projected Savings, But Key Questions Remain Unanswered

The Basic Facts

As of April 23, 2026, the Trump administration has finalized 17 Most-Favored-Nation (MFN) drug pricing agreements with the world's largest pharmaceutical manufacturers.

The list includes Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, and most recently, Regeneron — according to White House fact sheets dated December 19, 2025, and April 23, 2026.

Those 17 companies represent 86% of the branded drug market.

What MFN Actually Means

The concept is straightforward. Americans have been paying dramatically more for the same drugs than patients in Germany, France, Japan, or Canada. The MFN policy says: whatever price you offer in those countries, Americans get that price too.

The White House published a detailed policy report on May 5, 2026, projecting $529 billion in total domestic savings over 10 years across all markets — private insurance included.

An additional $64.3 billion in federal and state Medicaid savings is projected over that same decade by requiring manufacturers to offer existing drugs to state Medicaid programs at MFN prices.

Those are government-issued projections. But the underlying price cuts are documented and real.

Real Prices, Real Cuts

According to the White House, here's what patients can pay RIGHT NOW through the TrumpRx.gov direct-to-consumer platform:

• Repatha (Amgen, cholesterol): drops from $573 to $239
• Reyataz (Bristol Myers Squibb, HIV): drops from $1,449 to $217
• Jentadueto (Boehringer Ingelheim, type 2 diabetes): drops from $525 to $55
• Epclusa (Gilead Sciences, Hepatitis C): drops from $24,920 to $2,425
• Praluent (Regeneron, cholesterol): drops from $537 to $225

A Hepatitis C drug dropping from nearly $25,000 to $2,400 represents a 90% price cut.

For GLP-1 weight-loss drugs, uninsured patients are projected to save $3,000 per year. Couples doing IVF could save $6,000 per treatment cycle, according to the White House report.

The Regeneron Deal Had an Extra Twist

The 17th deal, with Regeneron, came with additional provisions. The company's new gene therapy for genetic deafness, called Otarmeni, will be provided to American patients at zero cost as part of the agreement, according to the April 23, 2026 White House fact sheet.

Regeneron also committed to investing $27 billion in U.S. research, development, and manufacturing by 2029 — with plans to more than double domestic biologics manufacturing capacity.

That represents a reshoring commitment. Pharmaceutical supply chain security has been a bipartisan concern since COVID exposed how much America depends on foreign production.

What Mainstream Media Is Getting Wrong

Left-leaning outlets have largely covered this either grudgingly or by burying the specifics, focusing instead on what wasn't done — like legislatively mandated price controls — rather than what was. The voluntary nature of these agreements deserves scrutiny, but dismissing documented price cuts because they're not legally binding misses the story.

Right-leaning outlets have largely treated this as a clean win with no caveats.

Here are the questions NOT being asked loudly enough:

One: These are voluntary agreements. What enforcement mechanism exists if a company decides to walk away in 2027? The White House says it's working with Congress to codify the agreements into law — but that hasn't happened yet. Voluntary agreements differ from legally binding ones.

Two: The TrumpRx.gov platform delivers the biggest price cuts — but only for patients buying outside of insurance. The proposed legislation to count those purchases toward deductibles and out-of-pocket maximums hasn't passed. Until it does, insured patients may see limited direct benefit.

Three: The $529 billion savings projection comes from the White House itself. That's not an independent CBO score. It deserves independent verification before being treated as definitive.

The Bipartisan Opening

One signal that this policy has real legs: according to reporting referenced by Axios, Senator Peter Welch — a Vermont Democrat — has indicated he would support Trump's MFN drug pricing framework. Welch is no moderate. When a progressive senator from Bernie Sanders' home state backs a Trump policy, it signals genuine cross-party support.

Drug pricing is one of the few issues where working-class Americans of both parties agree completely: they're getting ripped off.

What This Means for You

If you're uninsured or underinsured, TrumpRx.gov is worth checking right now. The price cuts are documented, the platform is live, and the drugs covered include some of the most commonly prescribed in America — diabetes, cholesterol, HIV, asthma, Hepatitis C.

If you're a taxpayer, $64 billion in Medicaid savings over 10 years is real money — assuming the agreements hold and get codified.

If you're paying attention, the critical question is whether voluntary deals become permanent law before the next administration or the next set of lobbyists decides to renegotiate the terms.

The price cuts are real. The long-term framework is still fragile.